| 05/12 | Erasca Narrows Q1 Loss, Misses Street Estimates | MT |
| 05/12 | Earnings Flash (ERAS) ERASCA Reports Q1 Loss $-0.31 | MT |
| 05/12 | Erasca Reports First Quarter 2022 Financial Results and Business Updates | GL |
| 05/12 | Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/03 | Erasca to Present at the Bank of America Securities 2022 Healthcare Conference | AQ |
| 04/27 | Erasca Appoints Jean Liu to its Board of Directors | AQ |
| 04/27 | Erasca Appoints Jean Liu to its Board of Directors | CI |
| 04/12 | Erasca Says Data Support Clinical Development of Certain Programs | MT |
| 04/12 | Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentia.. | AQ |
| 04/06 | Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportun.. | AQ |
| 03/25 | NORTH AMERICAN MORNING BRIEFING : Dow Futures -2- | DJ |
| 03/24 | ERASCA : Reports Fourth Quarter 2021 Financial Results and Business Updates - Form 8-K | PU |
| 03/24 | Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 | CI |
| 03/24 | Erasca, Inc. Expects Initial Phase 1b Monotherapy Data in Second Half of 2022 | CI |
| 03/24 | Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates | AQ |
| 03/24 | Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 03/18 | NORTH AMERICAN MORNING BRIEFING : Stock Futures -2- | DJ |
| 03/10 | Erasca, Eli Lilly to Collaborate in Oncologic Clinical Trial | MT |
| 03/10 | Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and C.. | AQ |
| 03/08 | Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting | AQ |
| 02/03 | Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day | AQ |
| 01/18 | Erasca Strengthens Leadership Team with Two Key Executive Appointments | GL |
| 01/18 | Erasca Strengthens Leadership Team with Two Key Executive Appointments | GL |
| 01/18 | Erasca, Inc. Announces Executive Changes | CI |
| 01/12 | Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-J.. | CI |
| 01/12 | Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-JA.. | CI |
| 01/04 | Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference | AQ |
| 01/03 | Guggenheim Adjusts Price Target for Erasca to $20 From $25, Maintains Buy Rating | MT |
| 2021 | ERASCA, INC.(NASDAQGS : ERAS) added to S&P Global BMI Index | CI |
| 2021 | ERASCA, INC.(NASDAQGS : ERAS) added to NASDAQ Biotechnology Index | CI |
| 2021 | Erasca Wins US FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme | MT |
| 2021 | Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multifor.. | GL |
| 2021 | Erasca, Inc. Announces FDA Clearance of IND Application for Eras-801 in Glioblastoma Mu.. | CI |
| 2021 | Erasca to Be Included in Nasdaq Biotechnology Index | MT |
| 2021 | Erasca Added to the Nasdaq Biotechnology Index | AQ |
| 2021 | Erasca, Inc. Announces Change of Address | CI |
| 2021 | Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference | AQ |
| 2021 | Erasca Reports Third Quarter 2021 Financial Results and Business Updates - Form 8-K | PU |
| 2021 | Earnings Flash (ERAS) ERASCA Reports Q3 Loss $-0.46 | MT |
| 2021 | Erasca Reports Third Quarter 2021 Financial Results and Business Updates | GL |
| 2021 | ERASCA : Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhi.. | AQ |
| 2021 | Erasca, Inc. Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EG.. | CI |
| 2021 | ERASCA : is Named One of Fierce Biotech's “Fierce 15” Biotechnology Companies .. | AQ |
| 2021 | ERASCA : Doses First Patient in Phase 1b/2 Trial of ERAS-007 in Gastrointestinal Cancer | MT |
| 2021 | ERASCA : Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer.. | AQ |
| 2021 | Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal.. | CI |
| 2021 | ERASCA, INC.(NASDAQGS : ERAS) added to S&P TMI Index | CI |
| 2021 | ERASCA : Doses First Patient in Lung Cancer Treatment Trial | MT |
| 2021 | Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protoc.. | GL |
| 2021 | Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protoc.. | CI |
| 2021 | ERASCA : Pfizer Collaborate on Colorectal Cancer Combo Therapy | MT |
| 2021 | Erasca in Clinical Trial Collaboration Agreement With Pfizer | DJ |
| 2021 | PFIZER : Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to.. | AQ |
| 2021 | ERASCA : to Participate in the Morgan Stanley 19th Annual Global Healthcare Virtual Confer.. | AQ |
| 2021 | ERASCA : Reports Second Quarter 2021 Financial Results and Business Updates (Form 8-K) | PU |
| 2021 | ERASCA : Q2 Loss Widens, Operating Expenses Rise | MT |
| 2021 | Erasca Reports Second Quarter 2021 Financial Results and Business Updates | GL |
| 2021 | ERASCA : Reports Second Quarter 2021 Financial Results and Business Updates | AQ |
| 2021 | ERASCA : Earnings Flash (ERAS) ERASCA Posts Q2 Loss $-1.20 | MT |
| 2021 | Earnings Flash (ERAS) ERASCA Posts Q2 Loss $-1.20 | MT |
| 2021 | Erasca, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and.. | CI |
| 2021 | ERASCA : Evercore ISI Starts Erasca at Outperform With $45 Price Target | MT |
| 2021 | ERASCA : Guggenheim Starts Erasca at Buy With $25 Price Target | MT |
| 2021 | ERASCA : BofA Securities Starts Erasca at Buy With $28 Price Target | MT |
| 2021 | ERASCA : JPMorgan Starts Erasca at Overweight With $28 Price Target | MT |
| 2021 | ERASCA : Morgan Stanley Starts Erasca at Equal-Weight With $25 Price Target | MT |
| 2021 | Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters' .. | GL |
| 2021 | ERASCA : Opens Lower in Nasdaq Debut, Gains By Afternoon | MT |
| 2021 | ERASCA : Prices IPO of 18.8 Million Common Shares at $16 per Share | MT |
| 2021 | Erasca Announces Pricing of Upsized Initial Public Offering | GL |
| 2021 | Erasca, Inc. has completed an IPO in the amount of $300 million. | CI |
| 2021 | Erasca, Inc. has filed an IPO in the amount of $100 million. | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
